August 1992
Volume 33, Issue 9
Free
Articles  |   August 1992
Immunomodulation of experimental autoimmune uveoretinitis by intravenous injection of uveitogenic peptides.
Author Affiliations
  • Y Sasamoto
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
  • Y I Kawano
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
  • R Bouligny
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
  • B Wiggert
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
  • G J Chader
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
  • I Gery
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
Investigative Ophthalmology & Visual Science August 1992, Vol.33, 2641-2649. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y Sasamoto, Y I Kawano, R Bouligny, B Wiggert, G J Chader, I Gery; Immunomodulation of experimental autoimmune uveoretinitis by intravenous injection of uveitogenic peptides.. Invest. Ophthalmol. Vis. Sci. 1992;33(9):2641-2649.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Intravenous (IV) injection of antigenic proteins induces specific unresponsiveness, as shown by the diminished response to a challenge with these proteins in complete Freund's adjuvant. This study examined the effect of IV treatment with uveitogenic peptides on the development of experimental autoimmune uveoretinitis (EAU). The peptides used were derived from the sequence of bovine interphotoreceptor retinoid-binding protein (IRBP) and included R16 (sequence, 1177-1191), which is immunodominant and highly uveitogenic, and R4 (sequence, 1158-1180), which is nondominant and weakly uveitogenic. The efficacy of this treatment was found to depend on both the dose used for the IV injection and that used for the challenge. Thus, EAU induced by R16 at a dose of 0.2 nmol/rat was inhibited completely in all rats treated with the peptide at doses of 400 or 133 nmol and partially by the low dose of 5 nmol/rat. However, the EAU induced by a R16 challenge of 40 nmol/rat was inhibited only partially by the high treatment dose of 400 nmol/rat. The IV treatment was found to be effective in inhibiting the EAU induced by peptide R4. A large dose of R4 was needed to induce EAU (40 nmol/rat), and the disease was inhibited completely in all rats treated IV with this peptide at doses of 800, 400, or 133 nmol. In most animals injected with the 44-nmol dose, also, inhibition was complete. These data show that there is a correlation between the doses needed for achieving inhibition and those used for the challenge. The ratios between these doses in all experiments were found within the range 1-20.(ABSTRACT TRUNCATED AT 250 WORDS)

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×